Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Puma Biotechnology, Inc.

< Previous 1 2 3 Next >
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Third Quarter 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Second Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports First Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Releases Updated Corporate Presentation
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.